[Continuous hepatic arterial infusion chemotherapy using implantable reservoir in liver metastases from colorectal cancer].
Continuous hepatic arterial infusion chemotherapy using implantable reservoir was performed for liver metastases from colorectal cancer, and the therapeutic effects, side effects, and complications were evaluated. 9 patients with unresectable liver metastases were as follows, 1. Group A; 3 patients, MMC 2 mg.one shot + 5-FU 250 mg/day.continuous infusion x 14 days, and then 5-FU tablets 150 mg/day.p.o. x 14 days, 2. Group B; 4 patients, MMC 2 mg.one shot + 5-FU 500 mg/day.continuous infusion x 7 days, and then 5-FU tablets 150 mg/day.p.o. x 14 days, 3. Group C; 2 patients, 5-FU 500 mg/day.continuous infusion x 14 days, and then free from agents for 14 days. In 2 of 3 group A patients, the catheters became dislocated and one died of perforation of duodenum. In group A and group B, no severe side effects were noted. But both of group C patients showed nausea, vomiting and diarrhea. In 8 of 9 patients (89%), serum CEA level fell below the preoperative level. In 4 of 7 patients who underwent CT scan, the size of the tumor regressed. Total infused dose of 5-FU was 8.17 +/- 7.56 g in group A, 16.9 +/- 2.88 g in group B, and 21.0 +/- 9.90 g in group C on average. In 2 patients of group B, therapy was repeated seven times.
Iijima
K
K
2nd Dept. of Surgery, School of Medicine, Yokohama City University.
Ohki
S
S
Joh
T
T
Nakajima
S
S
Imai
S
S
Matsuo
K
K
Hamahata
Y
Y
Yamaguchi
S
S
Fukano
M
M
Tsuchiya
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D015179:Colorectal Neoplasms / Q000473:pathology; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011379:Prognosis
D002272:Carcinoembryonic Antigen; D008937:Mitomycins; D016685:Mitomycin; D005472:Fluorouracil